COIOSDeep risk insights through multi-disciplinary research across the globe
white metal frame during daytime
Item new Peer-reviewed Added

Enterocolitis after BCMA-directed CAR T cell therapy resolved in about a third of patients

Enterocolitis after BCMA-directed CAR T cell therapy resolved by last follow-up in 32% of patients, with some deaths from complications.

The study described immune effector cell-associated enterocolitis, a gut inflammation seen after BCMA-directed CAR T cell therapy. It was a large case series of patients who developed the disorder across several treatment centres. Only 32% of patients had achieved resolution of the enterocolitis at last follow-up. Some deaths were directly attributed to complications of the disorder. As a case series it has no comparison group or incidence rate. Patient numbers and follow-up length are not reported.

Why it is interesting: BCMA-directed CAR T cell therapy is a recent form of treatment. In this series the related gut disorder was mostly unresolved at last follow-up, and some deaths followed from its complications.

Source
Nature Medicine, 19 November 2026
Type
Peer-reviewed article
Design
Multicentre retrospective case series of immune effector cell-associated enterocolitis after BCMA-directed CAR T therapy; n and years not stated in abstract
Verdict
New finding
Driver
Innovation in treatment

Other drivers in Tomorrow's world